Neurobiologia clinica

Condividi su

Gruppo guidato da Antonio Bertolotto

Neurobiologia clinica

Pubblicazioni

2017

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468.

Valentino P, Marnetto F, Granieri L, Capobianco M, Bertolotto A. Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study. Neurol Neuroimmunol Neuroinflamm 2017;4:e317; doi: 10.1212/ NXI.0000000000000317  PMID: 28054001

Clemente N, Comi C, Raineri D, Cappellano G, Vecchio D, Orilieri E, Gigliotti CL, Boggio E, Dianzani C, Sorosina M, Martinelli-Boneschi F, Caldano M, Bertolotto A, Ambrogio L, Sblattero D, Cena T, Leone M, Dianzani U and Chiocchetti A (2017) Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Front. Immunol. 8:321. doi: 10.3389/fimmu.2017.00321

Melillo F, Di Sapio A, Martire S, Malentacchi M, Matta M, Bertolotto A. Computerized posturography is more sensitive than clinical Romberg Test in detecting postural control impairment in minimally impaired Multiple Sclerosis patients. Mult Scler and Rel Dis, 14:51-55, 2017 ISSN 2211-0348, http://doi.org/10.1016/j.msard.2017.03.008.

Malucchi S, Capobianco M, Lo Re M, Malentacchi M, di Sapio A, Matta M, Sperli F, Bertolotto A  High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study. Neurol Ther. 2017 Jun;6(1):145-152. doi: 10.1007/s40120-016-0058-0. Epub 2016 Dec 3. PMID: 27915429

Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, Marfia GA, Sormani MP, Capra R, Centonze D; Italian PML study group. Collaborators: Amato MP, Bandini F, Bertolotto A, Brescia-Morra V, Cavaletti G, Cavalla P, Capobianco M, Clerico M, D'Aleo G, de Riz M, Deotto L, Durelli L, Falcini M, Ferrari E, Fusco ML, Gasperini C, Gerevini S, Ghezzi A, Grimaldi L, Guidotti M, Lugaresi A, Naldi P, Moiola L, Perrone P, Pizzorno M, Pozzilli C, Rezzonico M, Rovaris M, Salemi G, Salvetti M, Santuccio G, Scarpini E, Sessa E, Solaro C, Tabiadon G, Tortorella C, Trojano M  No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology. 2017 Mar 21;88(12):1144-1152. doi: 10.1212/WNL.0000000000003740 PMID: 28228569

Marnetto F, Valentino P, Caldano M, Bertolotto A. Detection of potassium channel KIR4.1 antibodies in Multiple Sclerosis patients.  J Immunol Methods. 2017 Mar 12. pii: S0022-1759(16)30395-7. doi: 10.1016/j.jim.2017.03.008. [Epub ahead of print] PMID: 28300540

Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry. Prognostic indicators in pediatric clinically isolated syndrome. Ann Neurol. 2017 May;81(5):729-739. doi: 10.1002/ana.24938. PMID: 28439957

Spadaro M, Montarolo F, Perga S, Martire S, Brescia F, Malucchi S, Bertolotto A Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10 years in responder multiple sclerosis patients Clin Immunol 181 (2017) 83–88 doi: 10.1016/j.clim.2017.06.006. PMID: 28642148

Gils A, Bertolotto A, Mulleman D, Bejan-Angoulvant T, Declerck PJ. Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases. Ther Drug Monit. 2017 Aug;39(4):308-315. doi: 10.1097/FTD.0000000000000385. PMID: 28230618

Paintaud G, Passot C, Ternant D, Bertolotto A, Bejan-Angoulvant T, Pascual-Salcedo D, Mulleman D. Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases. Ther Drug Monit. 2017 Aug;39(4):339-343. doi: 10.1097/FTD.0000000000000410. PMID: 28486309

Caldano M, Raoul W, Rispens T, Bertolotto A. Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis With Biological Agents.  Ther Drug Monit. 2017 Aug;39(4):350-355. doi: 10.1097/FTD.0000000000000393. PMID: 28328761

2016

Bertolotto A, Malentacchi M, Capobianco M, di Sapio A, Malucchi S, Motuzova Y, Pulizzi A, Berchialla P, Sperli F  The use of the 25 Sprotte needle markedly reduces post-dural puncture headache in routine neurological practice Cephalalgia 2016, 36: 131-138, doi:10.1177/0333102415583983

Carletto S, Borghi M, Francone D, Scavelli F, Bertino G, Cavallo M, Malucchi S, Bertolotto A, Oliva F, Ostacoli L. The efficacy of a Mindfulness Based Intervention for depressive symptoms in patients with Multiple Sclerosis and their caregivers: study protocol for a randomized controlled clinical trial. BMC Neurol. 2016 Jan 13;16(1):7. doi: 10.1186/s12883-016-0528-0. ISSN: 14712377 PMID: 26757728

Martire S, Navone ND, Montarolo F, Perga S, Bertolotto A. A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients. J Neuroimmunol. 2016 Mar 15;292:34-9. doi: 10.1016/j.jneuroim.2016.01.010. Epub 2016 Jan 16. PMID: 26943956

Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Mar 12;387(10023):1075-84. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28

Rosato R, Testa S, Bertolotto A, Confalonieri P, Patti F, Lugaresi A, Grasso MG, Toscano A, Giordano A, Solari A. Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory. PLoS One. 2016 Apr 14;11(4):e0153466. doi: 10.1371/journal.pone.0153466. eCollection 2016. PMID: 27078146

Hegen H, Adrianto I, Lessard CJ, Millonig A, Bertolotto A, Comabella M, Giovannoni G, Guger M, Hoelzl M, Khalil M, Fazekas F, Killestein J, Lindberg RL, Malucchi S, Mehling M, Montalban X, Rudzki D, Schautzer F, Sellebjerg F, Sorensen PS, Deisenhammer F, Steinman L, Axtell RC. Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(2):e202. doi: 10.1212/NXI.0000000000000202. eCollection 2016 Apr PMID: 26894205

Troni W, Melillo F, Bertolotto A, Malucchi S, Capobianco M, Sperli F, Di Sapio A. Normative Values for Intertrial Variability of Motor Responses to Nerve Root and Transcranial Stimulation: A Condition for Follow-Up Studies in Individual Subjects PLoS One. 2016 May 16;11(5):e0155268. doi: 10.1371/journal.pone.0155268. eCollection 2016. PMID: 27182973

Borghi M, Carletto S, Ostacoli L, Scavelli F, Pia L, Pagani M, Bertolotto A, Malucchi S, Signori A, Cavallo M. Decline of Neuropsychological Abilities in a Large Sample of Patients with Multiple Sclerosis: A Two-Year Longitudinal Study. Front Hum Neurosci. 2016 Jun 8;10:282. doi: 10.3389/fnhum.2016.00282. eCollection 2016. PMID: 27375468

Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Cantó E, Kümpfel T, Hohlfeld R, Siffrin V, Luessi F, Posevitz-Fejfár A, Montalban X, Meuth SG, Zipp F, Gold R, Du Pasquier RA, Kleinschnitz C, Jacobi A, Comabella M, Bertolotto A, Brassat D, Wiendl H. PML risk stratification using anti-JCV antibody index and L-selectin.  Mult Scler. 2016 Jul;22(8):1048-1060. Epub 2015 Oct 2. PMID: 26432858

Lanzillo R, Quarantelli M, Pozzilli C, Trojano M, Amato MP, Marrosu MG, Francia A, Florio C, Orefice G, Tedeschi G, Bellantonio P, Annunziata P, Grimaldi LM, Comerci M, Brunetti A, Bonavita V, Alfano B, Marini S, Brescia Morra V; ARIANNA study group. No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1a therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). Mult Scler. 2016 Aug;22(9):1163-73. doi: 10.1177/1352458515611222. Epub 2015 Oct 14. PMID: 26466947

Waters P, Reindl M, Saiz A, Schanda K, Tuller F, Kral V, Nytrova P, Sobek O, Nielsen HH, Barington T, Lillevang ST, Illes Z, Rentzsch K, Berthele A, Berki T, Granieri L, Bertolotto A, Giometto B, Zuliani L, Hamann D, van Pelt ED, Hintzen R, Höftberger R, Costa C, Comabella M, Montalban X, Tintoré M, Siva A, Altintas A, Deniz G, Woodhall M, Palace J, Paul F, Hartung HP, Aktas O, Jarius S, Wildemann B, Vedeler C, Ruiz A, Leite MI, Trillenberg P, Probst M, Saschenbrecker S, Vincent A, Marignier R. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):1005-15. doi: 10.1136/jnnp-2015-312601. PMID: 27113605

Patti F, Messina S, Solaro C, Amato MP, Bergamaschi R, Bonavita S, Bruno Bossio R, Brescia Morra V, Costantino GF, Cavalla P, Centonze D, Comi G, Cottone S, Danni M, Francia A, Gajofatto A, Gasperini C, Ghezzi A, Iudice A, Lus G, Maniscalco GT, Marrosu MG, Matta M, Mirabella M, Montanari E, Pozzilli C, Rovaris M, Sessa E, Spitaleri D, Trojano M, Valentino P, Zappia M; SA.FE. study group. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):944-51. doi: 10.1136/jnnp-2015-312591. Epub 2016 May 9. PMID: 27160523

Montarolo F, Perga S, Martire S, Navone DN, Marchet A, Leotta D, Bertolotto A. Altered NR4A Subfamily Gene Expression Level in Peripheral Blood of Parkinson's and Alzheimer's Disease Patients. Neurotox Res. 2016 Oct;30(3):338-44. doi: 10.1007/s12640-016-9626-4. Epub 2016 May 9. PMID: 27159982

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology. 2016 Nov 8;87(19):1985-1992. PMID: 27733571

Arnold DL, Fisher E, Brinar VV, Cohen JA, Coles AJ, Giovannoni G, Hartung HP, Havrdova E, Selmaj KW, Stojanovic M, Weiner HL, Lake SL, Margolin DH, Thomas DR, Panzara MA, Compston DA; CARE-MS I and CARE-MS II Investigators. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS. Neurology 2016 Oct 4;87(14):1464-1472 PMID: 27590291 PMCID: PMC5075976 DOI: 10.1212/WNL.0000000000003169

Chiavazza C, Cistaro A, Fania P, Bertolotto A, Cavalla P, Rudà R, Pinessi L, Soffietti R Reversible disconnection syndrome in a case of acute tumefactive demyelinating lesion: a PET study. Neurol Sci. 2016 Dec;37(12):2019-2023  PMID: 27457655

Marola S, Ferrarese A, Gibin E, Capobianco M, Bertolotto A, Enrico S, Solej M, Martino V, Destefano I, Nan. o M. Anal sphincter dysfunction in multiple sclerosis: an observation manometric study. Open Med. 2016; 11: 509-517DOI 10.1515/med-2016-0088